Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several
Our patent team filed our particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. This year we also filed a provisional patent
number 63-299,930 giving us broader protection on recent and projected developments on both our hydrogel and our particle components. This week we filed a continuation-in-part applications number
1774054 in the USA to expand the claims on our particle patent.
We are near completion on additional development work and intend to file expanded particle claims internationally using the Patent Cooperation Treaty, PCT, process. Additionally, building on the
substantial refinements to our hydrogel during the past two years, we also plan to file a new utility patent to protect these proprietary developments. We anticipate the filings will be completed
during the third quarter.
In closing Dr. Korenko stated, “We are continually striving to enhance and grow our Intellectual property portfolio to build value to our stakeholders and to strengthen our position as an
emerging leader in precision radionuclide therapy.”